美國三個病人使用“人民的希望”的情況

“Based on our review of the clinical and virological courses, we believe remdesivir’s contribution to efficacy remains unclear, and with a side-effect profile that may not be completely benign,” the RBC analysts wrote in a note to investors. “We continue to see a less than 50/50 possibility that the drug is ultimately proven effective.”

https://www.statnews.com/pharmalot/2020/03/13/gilead-coronavirus-covid19-clinical-trials/

 

所有跟帖： 

• statenews 的新聞觀點不能全信，尤其關於新藥。華爾街的分析家更不可靠 -nowayitsover- ♂ (0 bytes) () 03/14/2020 postreply 22:10:32

• 鏈接裏有原始論文，值得一讀 -吃與活- ♂ (0 bytes) () 03/15/2020 postreply 06:00:29

• 我覺得應該在輕型患者中多找人做controlled trial. 病重的就一律都給吧，反正現在沒有什麽好辦法 -viewfinder- ♀ (0 bytes) () 03/15/2020 postreply 04:04:02